Skip Navigation
Skip to contents

Intest Res : Intestinal Research

IMPACT FACTOR

Search

Page Path
HOME > Search
6 "Simon Travis"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Letters to the Editor
Miscellaneous
JAK inhibitor, a new player for treatment-refractory microscopic colitis
Anne Druez, Simon Travis, Jean-François Rahier
Intest Res 2023;21(3):411-412.   Published online July 4, 2023
DOI: https://doi.org/10.5217/ir.2023.00030
PDFPubReaderePub

Citations

Citations to this article as recorded by  
  • Endoscopic findings of immune checkpoint inhibitor-related gastrointestinal adverse events
    Min Kyu Kim, Sung Wook Hwang
    Clinical Endoscopy.2024; 57(6): 725.     CrossRef
  • 1,895 View
  • 108 Download
  • 1 Web of Science
  • 1 Crossref
Close layer
Review
IBD
Artificial intelligence in inflammatory bowel disease: implications for clinical practice and future directions
Harris A. Ahmad, James E. East, Remo Panaccione, Simon Travis, James B. Canavan, Keith Usiskin, Michael F. Byrne
Intest Res 2023;21(3):283-294.   Published online April 20, 2023
DOI: https://doi.org/10.5217/ir.2023.00020
AbstractAbstract PDFPubReaderePub
Inflammatory bowel disease encompasses Crohn’s disease and ulcerative colitis and is characterized by uncontrolled, relapsing, and remitting course of inflammation in the gastrointestinal tract. Artificial intelligence represents a new era within the field of gastroenterology, and the amount of research surrounding artificial intelligence in patients with inflammatory bowel disease is on the rise. As clinical trial outcomes and treatment targets evolve in inflammatory bowel disease, artificial intelligence may prove as a valuable tool for providing accurate, consistent, and reproducible evaluations of endoscopic appearance and histologic activity, thereby optimizing the diagnosis process and identifying disease severity. Furthermore, as the applications of artificial intelligence for inflammatory bowel disease continue to expand, they may present an ideal opportunity for improving disease management by predicting treatment response to biologic therapies and for refining the standard of care by setting the basis for future treatment personalization and cost reduction. The purpose of this review is to provide an overview of the unmet needs in the management of inflammatory bowel disease in clinical practice and how artificial intelligence tools can address these gaps to transform patient care.

Citations

Citations to this article as recorded by  
  • Deep Learning Model Using Stool Pictures for Predicting Endoscopic Mucosal Inflammation in Patients With Ulcerative Colitis
    Jung Won Lee, Dongwon Woo, Kyeong Ok Kim, Eun Soo Kim, Sung Kook Kim, Hyun Seok Lee, Ben Kang, Yoo Jin Lee, Jeongseok Kim, Byung Ik Jang, Eun Young Kim, Hyeong Ho Jo, Yun Jin Chung, Hanjun Ryu, Soo-Kyung Park, Dong-Il Park, Hosang Yu, Sungmoon Jeong
    American Journal of Gastroenterology.2025; 120(1): 213.     CrossRef
  • The Histological Detection of Ulcerative Colitis Using a No-Code Artificial Intelligence Model
    Yuichiro Hamamoto, Michihiro Kawamura, Hiroki Uchida, Kazuhiro Hiramatsu, Chiaki Katori, Hinako Asai, Shigeki Shimizu, Satoshi Egawa, Kyotaro Yoshida
    International Journal of Surgical Pathology.2024; 32(5): 890.     CrossRef
  • Could histologic healing be a new treatment target in patients with ulcerative colitis?
    Soyoung Kim, Sang Hyoung Park
    The Korean Journal of Internal Medicine.2024; 39(1): 2.     CrossRef
  • Machine learning in the assessment and management of acute gastrointestinal bleeding
    Gaurav Bhaskar Nigam, Michael F Murphy, Simon P L Travis, Adrian J Stanley
    BMJ Medicine.2024; 3(1): e000699.     CrossRef
  • The Role of Artificial Intelligence in the Diagnosis and Treatment of Ulcerative Colitis
    Petar Uchikov, Usman Khalid, Nikola Vankov, Maria Kraeva, Krasimir Kraev, Bozhidar Hristov, Milena Sandeva, Snezhanka Dragusheva, Dzhevdet Chakarov, Petko Petrov, Bistra Dobreva-Yatseva, Ivan Novakov
    Diagnostics.2024; 14(10): 1004.     CrossRef
  • Artificial intelligence and endo-histo-omics: new dimensions of precision endoscopy and histology in inflammatory bowel disease
    Marietta Iacucci, Giovanni Santacroce, Irene Zammarchi, Yasuharu Maeda, Rocío Del Amor, Pablo Meseguer, Bisi Bode Kolawole, Ujwala Chaudhari, Antonio Di Sabatino, Silvio Danese, Yuichi Mori, Enrico Grisan, Valery Naranjo, Subrata Ghosh
    The Lancet Gastroenterology & Hepatology.2024; 9(8): 758.     CrossRef
  • Summary of the best evidence on self-management support schemes for patients with inflammatory bowel disease based on mobile health systems
    Chenfei Ren, Yunxian Zhou, Qian Cai, Mi Zhou
    DIGITAL HEALTH.2024;[Epub]     CrossRef
  • Deep Learning-Based Real-Time Organ Localization and Transit Time Estimation in Wireless Capsule Endoscopy
    Seung-Joo Nam, Gwiseong Moon, Jung-Hwan Park, Yoon Kim, Yun Jeong Lim, Hyun-Soo Choi
    Biomedicines.2024; 12(8): 1704.     CrossRef
  • The Role of Artificial Intelligence and Big Data for Gastrointestinal Disease
    Nicholas Mathew Holt, Michael Francis Byrne
    Gastrointestinal Endoscopy Clinics of North America.2024;[Epub]     CrossRef
  • Dye-based chromoendoscopy detects more neoplasia than white light endoscopy in patients with primary sclerosing cholangitis and IBD
    Rodrigo V Motta, Vipin Gupta, Karen Hartery, Paul Bassett, Simon J Leedham, Roger W Chapman, Simon PL Travis, Emma L Culver, James E. East
    Endoscopy International Open.2024; 12(11): E1285.     CrossRef
  • Potential Oral Microbial Markers for Differential Diagnosis of Crohn’s Disease and Ulcerative Colitis Using Machine Learning Models
    Sang-Bum Kang, Hyeonwoo Kim, Sangsoo Kim, Jiwon Kim, Soo-Kyung Park, Chil-Woo Lee, Kyeong Ok Kim, Geom-Seog Seo, Min Suk Kim, Jae Myung Cha, Ja Seol Koo, Dong-Il Park
    Microorganisms.2023; 11(7): 1665.     CrossRef
  • 6,077 View
  • 354 Download
  • 11 Web of Science
  • 11 Crossref
Close layer
Original Article
Inflammatory bowel diseases
Real-time data monitoring for ulcerative colitis: patient perception and qualitative analysis
Alissa Walsh, Lawrence Matini, Christopher Hinds, Vanashree Sexton, Oliver Brain, Satish Keshav, John Geddes, Guy Goodwin, Gary Collins, Simon Travis, Michele Peters
Intest Res 2019;17(3):365-374.   Published online May 31, 2019
DOI: https://doi.org/10.5217/ir.2018.00173
AbstractAbstract PDFPubReaderePub
Background/Aims
TrueColours ulcerative colitis (TCUC) is a comprehensive web-based program that functions through email, providing direct links to questionnaires. Several similar programs are available, however patient perspectives are unexplored.
Methods
A pilot study was conducted to determine feasibility, usability and patient perceptions of real-time data collection (daily symptoms, fortnightly quality of life, 3 monthly outcomes). TCUC was adapted from a web-based program for patients with relapsing-remitting bipolar disorder, using validated UC indices. A semi-structured interview was developed and audio-recorded face-to-face interviews were conducted after 6 months of interaction with TCUC. Transcripts were coded in NVivo11, a qualitative data analysis software package. An inductive approach and thematic analysis was conducted.
Results
TCUC was piloted in 66 patients for 6 months. Qualitative analysis currently defies statistical appraisal beyond “data saturation,” even if it has more influence on clinical practice than quantitative data. A total of 28 face-to-face interviews were conducted. Six core themes emerged: awareness, control, decision-making, reassurance, communication and burden of treatment. There was a transcending overarching theme of patient empowerment, which cut across all aspects of the TCUC experience.
Conclusions
Patient perception of the impact of real-time data collection was extremely positive. Patients felt empowered as a product of the self-monitoring format of TCUC, which may be a way of improving self-management of UC whilst also decreasing the burden on the individual and healthcare services.

Citations

Citations to this article as recorded by  
  • Investigating Patient Perspectives on Using eHealth Technologies for the Self-Management of Inflammatory Bowel Disease: Mixed Methods Study
    Sander Hermsen, Danielle Tump, Eva Wentink, Marjolijn Duijvestein
    Journal of Medical Internet Research.2024; 26: e53512.     CrossRef
  • The body as an obstacle and the “other”. How patients with chronic inflammatory bowel diseases view their body, self and the good life
    Anke Erdmann, Christoph Rehmann-Sutter, Florian Schrinner, Claudia Bozzaro
    BMC Medical Ethics.2024;[Epub]     CrossRef
  • Development of the Escalation of Therapy or Intervention (ETI) Calculator for Patients with Ulcerative Colitis Using ePROMs
    Lawrence Matini, Thomas P Chapman, Ramona Kantschuster, Jean Wilson, Adib Tarafdar, Moheez Hussain, Kaiyang Song, Daniel M Simadibrata, Pavetha Seeva, Lydia White, Jessica Slater, Andrey Kormilitzin, Gary Collins, Simon P L Travis, Alissa Walsh
    Journal of Crohn's and Colitis.2023; 17(11): 1744.     CrossRef
  • Deep learning model for distinguishing Mayo endoscopic subscore 0 and 1 in patients with ulcerative colitis
    Ji Eun Kim, Yoon Ho Choi, Yeong Chan Lee, Gyeol Seong, Joo Hye Song, Tae Jun Kim, Eun Ran Kim, Sung Noh Hong, Dong Kyung Chang, Young-Ho Kim, Soo-Yong Shin
    Scientific Reports.2023;[Epub]     CrossRef
  • Patient-reported Outcomes: the ICHOM Standard Set for Inflammatory Bowel Disease in Real-life Practice Helps Quantify Deficits in Current Care
    Darren Wong, Lawrence Matini, Andrey Kormilitzin, Ramona Kantschuster, Daniel Martin Simadibrata, Sara Lyden, Jean Wilson, Oliver A Brain, Rebecca Palmer, Tim Ambrose, Jack Satsangi, Matthew South, John Geddes, Keith Bodger, Simon P L Travis, Alissa Walsh
    Journal of Crohn's and Colitis.2022; 16(12): 1874.     CrossRef
  • Analysis of the Current Situation of Teaching and Learning of Ideological and Political Theory Courses by Deep Learning
    Jin Chao, Yijiang Zhang, Arpit Bhardwaj
    Computational Intelligence and Neuroscience.2022; 2022: 1.     CrossRef
  • Ulcerative Colitis Narrative Global Survey Findings: Communication Gaps and Agreements Between Patients and Physicians
    David T Rubin, Ailsa Hart, Remo Panaccione, Alessandro Armuzzi, Ulla Suvanto, J Jasper Deuring, John Woolcott, Joseph C Cappelleri, Kathy Steinberg, Laura Wingate, Stefan Schreiber
    Inflammatory Bowel Diseases.2021; 27(7): 1096.     CrossRef
  • Telehealth and mobile health interventions in adults with inflammatory bowel disease: A mixed‐methods systematic review
    Suja P. Davis, Megan Suzanne Hardin Ross, Reuben Adatorwovor, Holly Wei
    Research in Nursing & Health.2021; 44(1): 155.     CrossRef
  • COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist
    Richard H. Hunt, James E. East, Angel Lanas, Peter Malfertheiner, Jack Satsangi, Carmelo Scarpignato, Gwilym J. Webb
    Digestive Diseases.2021; 39(2): 119.     CrossRef
  • The True Colours Remote Symptom Monitoring System: A Decade of Evolution
    Sarah M Goodday, Lauren Atkinson, Guy Goodwin, Kate Saunders, Matthew South, Clare Mackay, Mike Denis, Chris Hinds, Mary-Jane Attenburrow, Jim Davies, James Welch, William Stevens, Karen Mansfield, Juulia Suvilehto, John Geddes
    Journal of Medical Internet Research.2020; 22(1): e15188.     CrossRef
  • Developments and challenges of e-health strategies for people with inflammatory bowel disease
    Pearl Avery
    British Journal of Healthcare Management.2020; 26(3): 73.     CrossRef
  • Pathogenesis and clinical perspectives of extraintestinal manifestations in inflammatory bowel diseases
    Jung Min Kim, Jae Hee Cheon
    Intestinal Research.2020; 18(3): 249.     CrossRef
  • The UK IBD Registry COVID-19 Risk Tool; Patient Generated Data Can Improve the Hospital Record
    Nicholas A. Kennedy, Naila Arebi, Keith Bodger, Vida Cairnes, R. Fraser Cummings, Liz Dobson, Stephen Grainger, Paul Harrow, A. Barney Hawthorne, Gareth-Rhys Jones, Alexandra Kent, Shaji Sebastian, Christian Selinger, Gareth J. Walker, Lisa Younge, Stuart
    SSRN Electronic Journal .2020;[Epub]     CrossRef
  • 64,081 View
  • 139 Download
  • 13 Web of Science
  • 13 Crossref
Close layer
Reviews
IBD
Improving the quality of care for inflammatory bowel disease
Byong Duk Ye, Simon Travis
Intest Res 2019;17(1):45-53.   Published online November 20, 2018
DOI: https://doi.org/10.5217/ir.2018.00113
AbstractAbstract PDFPubReaderePub
Great strides have been achieved in the development of quality-of-care measures and standards for inflammatory bowel disease (IBD) over the last decade. The central structural component of care in IBD revolves around the multidisciplinary team, which should be equipped with the necessary resources to operate and implement decisions. Process measures have been defined by interest groups and can be adapted into process tools for the delivery of care for various patient subgroups and clinical scenarios. The emerging treat-to-target approach to IBD management may be used to achieve optimal long-term and holistic patient-centred outcomes, such as survival, control of inflammation and disease progression, symptomatic remission, quality of life and complications. Other important quality-of-care outcome measures for IBD include disutility of care, healthcare utilization and other patient-reported outcomes such as nutritional status and impact of fistulae. The current challenge for healthcare providers and health systems is the integration of quality-of-care structures and processes into clinical practice, and the consistent delivery of updated evidence-based quality IBD care to various patient populations by individual health care providers. Finally, the awareness and appreciation for quality of care in IBD is increasing in Asia, and Asian healthcare institutions should be encouraged to take the lead in improving the quality of care in IBD.

Citations

Citations to this article as recorded by  
  • Improving access to inflammatory bowel disease care in Canada: The patient experience
    Shehzeen Lalani, Holly Mathias, Courtney Heisler, Noelle Rohatinsky, Raza M Mirza, Olga Kits, Sandra Zelinsky, Geoffrey Nguyen, Peter L Lakatos, Sharyle Fowler, Kevin Rioux, Jennifer L Jones
    Journal of Health Services Research & Policy.2025; 30(1): 12.     CrossRef
  • Identification and prioritization of patient-centred strategies to enhance IBD-related care for older adults: a modified Delphi approach
    Noelle Rohatinsky, Natasha Tooke, Sharyle Fowler, Christian Rueda-Clausen, Dirk Morrison, Judith Winchester, Juan-Nicolás Peña-Sánchez
    Journal of the Canadian Association of Gastroenterology.2024; 7(5): 384.     CrossRef
  • Person-Centered Coordinated Care Experience of People With Long-Term Conditions in the Balearic Islands Measured by the P3CEQ
    Gabriel Mercadal-Orfila, Salvador Herrera-Pérez, Núria Piqué, Francesc Mateu-Amengual, Pedro Ventayol-Bosch, Maria Antonia Maestre-Fullana, Joaquin Ignacio Serrano-López de las Hazas, Francisco Fernández-Cortés, Francesc Barceló- Sansó, Santiago Rios
    Health Services Insights.2024;[Epub]     CrossRef
  • Empowering inflammatory bowel disease patients with at-home remote disease and therapeutic drug monitoring
    Graham Johnson
    Gastrointestinal Nursing.2024; 22(7): 337.     CrossRef
  • Holistic healthcare in inflammatory bowel disease: time for patient-centric approaches?
    Padhmanand Sudhakar, Judith Wellens, Bram Verstockt, Marc Ferrante, João Sabino, Séverine Vermeire
    Gut.2023; 72(1): 192.     CrossRef
  • The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission
    Johan Burisch, Mirabella Zhao, Selwyn Odes, Peter De Cruz, Severine Vermeire, Charles N Bernstein, Gilaad G Kaplan, Dana Duricova, Dan Greenberg, Hans O Melberg, Mamoru Watanabe, Hyeong Sik Ahn, Laura Targownik, Valérie E H Pittet, Vito Annese, KT Park, K
    The Lancet Gastroenterology & Hepatology.2023; 8(5): 458.     CrossRef
  • The 2023 Impact of Inflammatory Bowel Disease in Canada: Access to and Models of Care
    Holly Mathias, Noelle Rohatinsky, Sanjay K Murthy, Kerri Novak, M Ellen Kuenzig, Geoffrey C Nguyen, Sharyle Fowler, Eric I Benchimol, Stephanie Coward, Gilaad G Kaplan, Joseph W Windsor, Charles N Bernstein, Laura E Targownik, Juan-Nicolás Peña-Sánchez, K
    Journal of the Canadian Association of Gastroenterology.2023; 6(Supplement): S111.     CrossRef
  • Der IBD-Control-Fragebogen: Deutsche Übertragung und Validierung des standardisierten Fragebogens zur Messung des Outcomes aus Patientensicht bei chronisch entzündlichen Darmerkrankungen
    Annabell Müller, Selina Simone Bilger, Andreas Göldi, Gunther Meinlschmidt, Florian Rueter, Alexander Kappes, Petr Hruz, Christoph Andreas Meier, Jan Hendrik Niess
    Zeitschrift für Gastroenterologie.2022; 60(06): 911.     CrossRef
  • High Risk of Fractures Within 7 Years of Diagnosis in Asian Patients With Inflammatory Bowel Diseases
    Hyung Jin Ahn, Ye-Jee Kim, Ho-Su Lee, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Beom-Jun Kim, Sang Hyoung Park
    Clinical Gastroenterology and Hepatology.2022; 20(5): e1022.     CrossRef
  • Appendiceal Orifice Inflammation Is Associated with Lower Rate of Complete Endoscopic Remission in Patients with Ulcerative Colitis
    Chang Kyo Oh, Han Hee Lee, Jin Su Kim, Bo-In Lee, Young-Seok Cho
    Journal of Personalized Medicine.2022; 12(5): 748.     CrossRef
  • Risk of Hepatitis B Virus (HBV) Reactivation in Patients with Immune-Mediated Inflammatory Diseases Receiving Biologics: Focus on the Timing of Biologics after Anti-HBV Treatment
    Soo Min Ahn, Jonggi Choi, Byong Duk Ye, Suk-Kyun Yang, Ji Seon Oh, Yong‑Gil Kim, Chang-Keun Lee, Bin Yoo, Sang Hyoung Park, Seokchan Hong
    Gut and Liver.2022; 16(4): 567.     CrossRef
  • Clinical Remission and Psychological Management are Major Issues for the Quality of Life in Pediatric Crohn Disease
    Anne Gourdonneau, Léa Bruneau, Frank M. Ruemmele, Lorenzo Norsa, Armelle Takeda, Catherine Le Gall, Haude Clouzeau, Laurent Rebouissoux, Alain Dabadie, Laure Bridoux‐Henno, Julie Rebeuh, Nadège Thomassin, Jérôme Viala, Stéphanie Willot, Anne Breton, Stéph
    Journal of Pediatric Gastroenterology and Nutrition.2021; 72(1): 74.     CrossRef
  • Trends in hospitalizations and mortality for inflammatory bowel disease from a nationwide database study between 2008 and 2018
    Asim Kichloo, Zain El-amir, Dushyant Singh Dahiya, Farah Wani, Hafeez Shaka
    Baylor University Medical Center Proceedings.2021; 34(5): 550.     CrossRef
  • Classification According to Subjectivity of Inflammatory Bowel Disease Patients Using Q Methodology
    Jun Lee
    The Korean Journal of Gastroenterology.2021; 78(1): 1.     CrossRef
  • Subjective Needs and Thoughts for the Treatment of Patients with Inflammatory Bowel Disease: Applying Q Methodology
    Yong Eun Park, Jin Lee, Jongha Park, Joon Hyuk Choi, Nae Yun Heo, Seung Ha Park, Yoon Kyoung Lee, Tae Oh Kim
    The Korean Journal of Gastroenterology.2021; 78(1): 37.     CrossRef
  • Improving the care of inflammatory bowel disease (IBD) patients: perspectives and strategies for IBD center management
    Jihye Park, Sinyoung Park, Shin Ae Lee, Soo Jung Park, Jae Hee Cheon
    The Korean Journal of Internal Medicine.2021; 36(5): 1040.     CrossRef
  • Risk and characteristics of tuberculosis after anti-tumor necrosis factor therapy for inflammatory bowel disease: a hospital-based cohort study from Korea
    Jae Yong Lee, Kyunghwan Oh, Hee Seung Hong, Kyuwon Kim, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Ho-Su Lee, Kyung-Wook Jo, Sang Hyoung Park
    BMC Gastroenterology.2021;[Epub]     CrossRef
  • Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases
    Soo-Kyung Park, Chang Hwan Choi, Jaeyoung Chun, Heeyoung Lee, Eun Sun Kim, Jae Jun Park, Chan Hyuk Park, Bo-In Lee, Yunho Jung, Dong-Il Park, Do Young Kim, Hana Park, Yoon Tae Jeen
    Intestinal Research.2020; 18(1): 18.     CrossRef
  • Nationwide improvement in outcomes of emergency admission for ulcerative colitis in England, 2005‐2013
    Mustafa Shawihdi, Susanna Dodd, Constantinos Kallis, Pete Dixon, Ruth Grainger, Stuart Bloom, Fraser Cummings, Mike Pearson, Keith Bodger
    Alimentary Pharmacology & Therapeutics.2019; 50(2): 176.     CrossRef
  • 8,026 View
  • 257 Download
  • 20 Web of Science
  • 19 Crossref
Close layer
IBD
What's app? Electronic health technology in inflammatory bowel disease
Alissa Walsh, Simon Travis
Intest Res 2018;16(3):366-373.   Published online July 27, 2018
DOI: https://doi.org/10.5217/ir.2018.16.3.366
AbstractAbstract PDFPubReaderePub

Electronic health (eHealth) data collection is increasingly used in many chronic illnesses, to track pattern of disease. eHealth systems have the potential to revolutionize care. Inflammatory bowel disease (IBD) is a paradigm for such an approach: this is a chronic disease that usually affects young and technologically literate patient population, who are motivated to be involved in their own care. A range of eHealth technologies are available for IBD. This review considers the strengths and weaknesses of 7 platforms that focus on patient-provider interaction. These have been developed in Denmark, United States, the Netherlands, and the United Kingdom, demonstrating an international interest in this form of technology and interaction. Not only do these technologies aim to improve care but they also have the potential to collect large amounts of information. Information includes demographics and patient reported outcomes (symptoms, quality of life), quality of care (steroid use, among other metrics) and outcomes such as hospitalization. These data could inform quality improvement programmes to improve their focus. eHealth technology is also open to machine learning to analyze large data sets, through which personalized algorithms may be developed.

Citations

Citations to this article as recorded by  
  • Validation of the IBD-Control Questionnaire across different sociodemographic and clinical subgroups: secondary analysis of a nationwide electronic survey
    Gerum G Gebeyehu, Frederick Taylor, Liz Dobson, J R Fraser Cummings, Stuart Bloom, Nicholas A Kennedy, Paul Christiansen, Keith Bodger
    Journal of Crohn's and Colitis.2024; 18(2): 275.     CrossRef
  • Investigating Patient Perspectives on Using eHealth Technologies for the Self-Management of Inflammatory Bowel Disease: Mixed Methods Study
    Sander Hermsen, Danielle Tump, Eva Wentink, Marjolijn Duijvestein
    Journal of Medical Internet Research.2024; 26: e53512.     CrossRef
  • How can pharmacists better support patients with chronic diseases? The patient perspective
    Lakesha Butler, Steven Zona, Aarti A. Patel, Christine Brittle, Lisa Shea
    Journal of the American Pharmacists Association.2023; 63(6): 1776.     CrossRef
  • Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives
    Konstantinos Papamichael, Waqqas Afif, David Drobne, Marla C Dubinsky, Marc Ferrante, Peter M Irving, Nikolaos Kamperidis, Taku Kobayashi, Paulo G Kotze, Jo Lambert, Nurulamin M Noor, Xavier Roblin, Giulia Roda, Niels Vande Casteele, Andres J Yarur, Naila
    The Lancet Gastroenterology & Hepatology.2022; 7(2): 171.     CrossRef
  • Telemedicine based on patient-reported outcomes in management of patients with inflammatory bowel disease in a real-life setting – a before and after cohort study
    Charlotte W. Appel, Sarah Christine Pedersen, Amalie Søgaard Nielsen, Birgit Furstrand Larsen
    Scandinavian Journal of Gastroenterology.2022; 57(7): 825.     CrossRef
  • Readiness, acceptance and use of digital patient reported outcome in an outpatient clinic
    Amalie Søgaard Nielsen, Lisa Hanna, Birgit Furstrand Larsen, Charlotte W Appel, Richard H Osborne, Lars Kayser
    Health Informatics Journal.2022;[Epub]     CrossRef
  • The International Association of Dental Traumatology ToothSOS mobile app: A 2‐year report
    Anahat Khehra, Nestor Cohenca, Zafer C. Cehreli, Liran Levin
    Dental Traumatology.2021; 37(1): 145.     CrossRef
  • Telehealth and mobile health interventions in adults with inflammatory bowel disease: A mixed‐methods systematic review
    Suja P. Davis, Megan Suzanne Hardin Ross, Reuben Adatorwovor, Holly Wei
    Research in Nursing & Health.2021; 44(1): 155.     CrossRef
  • Real-life pilot study on the impact of the telemedicine platform EasyMICI–MaMICI® on quality of life and quality of care in patients with inflammatory bowel disease
    Guillaume Bonnaud, Audrey Haennig, Romain Altwegg, Bénédicte Caron, Lucile Boivineau, Camille Zallot, Cyrielle Gilleta de Saint-Joseph, Jacques Moreau, Florent Gonzalez, Didier Reynaud, Patrick Faure, Philippe Aygalenq, Jean Marc Combis, Laurent Peyrin-Bi
    Scandinavian Journal of Gastroenterology.2021; 56(5): 530.     CrossRef
  • Patient Reported Outcomes in Chronic Inflammatory Diseases: Current State, Limitations and Perspectives
    Florian Tran, Jan Henrik Schirmer, Ilka Ratjen, Wolfgang Lieb, Philip Helliwell, Johan Burisch, Juliane Schulz, Florian Schrinner, Charlot Jaeckel, Ulf Müller-Ladner, Stefan Schreiber, Bimba F. Hoyer
    Frontiers in Immunology.2021;[Epub]     CrossRef
  • Researching Interventions to Improve Medication Adherence in Ulcerative Colitis Patients
    Mila Palma Pacheco, Flora Maria Lorenzo Fortes, Raquel Rocha dos Santos, Genoile Oliveira Santana Silva
    Journal of Coloproctology.2021; 41(01): 096.     CrossRef
  • Mobile app requirements for patients with rare liver diseases: A single center survey for the ERN RARE-LIVER‬‬‬
    Darius F. Rüther, Marcial Sebode, Ansgar W. Lohse, Sarah Wernicke, Erwin Böttinger, Christian Casar, Felix Braun, Christoph Schramm
    Clinics and Research in Hepatology and Gastroenterology.2021; 45(6): 101760.     CrossRef
  • E‐Health and remote management of patients with inflammatory bowel disease: lessons from Denmark in a time of need
    Dorit V. Ankersen, Savannah Noack, Pia Munkholm, Miles P. Sparrow
    Internal Medicine Journal.2021; 51(8): 1207.     CrossRef
  • Patient Experience and Satisfaction with an e-Health Care Management Application for Inflammatory Bowel Diseases
    Aria Zand, Audrey Nguyen, Courtney Reynolds, Ariela Khandadash, Eric Esrailian, Daniel Hommes
    International Journal of Environmental Research and Public Health.2021; 18(22): 11747.     CrossRef
  • Developments and challenges of e-health strategies for people with inflammatory bowel disease
    Pearl Avery
    British Journal of Healthcare Management.2020; 26(3): 73.     CrossRef
  • Development and feasibility of a telemonitoring tool with full integration in the electronic medical record: a proof of concept study for patients with inflammatory bowel disease in remission on biological therapy
    Sofie Coenen, Egon Nijns, Ellen Weyts, Patricia Geens, Bart Van den Bosch, Séverine Vermeire, Marc Ferrante, Kris Vanhaecht, Gert Van Assche
    Scandinavian Journal of Gastroenterology.2020; 55(3): 287.     CrossRef
  • Organisational changes and challenges for inflammatory bowel disease services in the UK during the COVID-19 pandemic
    Nicholas A Kennedy, Richard Hansen, Lisa Younge, Joel Mawdsley, R Mark Beattie, Shahida Din, Christopher A Lamb, Philip J Smith, Christian Selinger, Jimmy Limdi, Tariq H Iqbal, Alan Lobo, Rachel Cooney, Oliver Brain, Daniel R Gaya, Charles Murray, Richard
    Frontline Gastroenterology.2020; 11(5): 343.     CrossRef
  • Crohn’s Colitis Care (CCCare): bespoke cloud-based clinical management software for inflammatory bowel disease
    Krupa Krishnaprasad, Alissa Walsh, Jakob Begun, Sally Bell, David Carter, Rachel Grafton, Alexandra Sechi, Karen Sewell, Anna McMahon, Susan Connor, Graham Radford-Smith, Jane M. Andrews
    Scandinavian Journal of Gastroenterology.2020; 55(12): 1419.     CrossRef
  • Exploring the Challenges of Implementing a Web-Based Telemonitoring Strategy for Teenagers With Inflammatory Bowel Disease: Empirical Case Study
    Alie Dijkstra, Anke Heida, Patrick Ferry van Rheenen
    Journal of Medical Internet Research.2019; 21(3): e11761.     CrossRef
  • Digital Health Apps in the Clinical Care of Inflammatory Bowel Disease: Scoping Review
    Andrew Lukas Yin, David Hachuel, John P Pollak, Ellen J Scherl, Deborah Estrin
    Journal of Medical Internet Research.2019; 21(8): e14630.     CrossRef
  • 8,957 View
  • 148 Download
  • 20 Web of Science
  • 20 Crossref
Close layer
Original Article
Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease
Kai-Chun Wu, Zhi Hua Ran, Xiang Gao, Minhu Chen, Jie Zhong, Jian-Qiu Sheng, Michael A Kamm, Simon Travis, Kori Wallace, Nael M Mostafa, Marisa Shapiro, Yao Li, Roopal B Thakkar, Anne M Robinson
Intest Res 2016;14(2):152-163.   Published online April 27, 2016
DOI: https://doi.org/10.5217/ir.2016.14.2.152
AbstractAbstract PDFSupplementary MaterialPubReaderePub
<b>Background/Aims</b><br/>

This was a Phase 2 study (NCT02015793) to evaluate the pharmacokinetics, safety, and efficacy of adalimumab in Chinese patients with Crohn's disease (CD).

Methods

Thirty, adult Chinese patients with CD (CD Activity Index [CDAI] 220–450; high-sensitivity [hs]-C-reactive protein [CRP] ≥3 mg/L) received double-blind adalimumab 160/80 mg or 80/40 mg at weeks 0/2, followed by 40 mg at weeks 4 and 6. An open-label extension period occurred from weeks 8–26; patients received 40 mg adalimumab every other week. Serum adalimumab concentration and change from baseline in fecal calprotectin (FC) were measured during the double-blind period. Clinical remission (CDAI <150), response (decrease in CDAI ≥70 points from baseline), and change from baseline in hs-CRP were assessed through week 26. Nonresponder imputation was used for missing categorical data and last observation carried forward for missing hs-CRP/FC values. No formal hypothesis was tested. Adverse events were monitored.

Results

Mean adalimumab serum concentrations during the induction phase were 13.9–18.1 µg/mL (160/80 mg group) and 7.5−9.5 µg/mL (80/40 mg group). During the double-blind period, higher remission/response rates and greater reductions from baseline in hs-CRP and FC were observed with adalimumab 160/80 mg compared to that with 80/40 mg. Adverse event rates were similar among all treatment groups.

Conclusions

Adalimumab serum concentrations in Chinese patients with CD were comparable to those observed previously in Western and Japanese patients. Clinically meaningful remission rates and improvement in inflammatory markers were achieved with both dosing regimens; changes occurred rapidly with adalimumab 160/80 mg induction therapy. No new safety signals were reported.

Citations

Citations to this article as recorded by  
  • Prospective study of an adalimumab combined with partial enteral nutrition in the induction period of Crohn’s disease
    Sisi Zhou, Zeyu Huang, Wenjing Hou, Yiting Lin, Jing Yu
    Inflammation Research.2024; 73(2): 199.     CrossRef
  • Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn’s disease: systematic review and network meta-analysis
    Brigida Barberio, David J Gracie, Christopher J Black, Alexander C Ford
    Gut.2023; 72(2): 264.     CrossRef
  • Seronegative spondyloarthropathy-associated inflammatory bowel disease
    Chrong-Reen Wang, Hung-Wen Tsai
    World Journal of Gastroenterology.2023; 29(3): 450.     CrossRef
  • Early Change in Fecal Calprotectin Predicts One‐Year Outcome in Children Newly Diagnosed With Ulcerative Colitis
    Chenthan Krishnakumar, Ashwin N. Ananthakrishnan, Brendan M. Boyle, Anne M. Griffiths, Neal S. LeLeiko, David R. Mack, James F. Markowitz, Joel R. Rosh, Cary G. Sauer, Thomas D. Walters, Erin Bonkowski, Lee A. Denson, Jeffrey S. Hyams, Subra Kugathasan
    Journal of Pediatric Gastroenterology and Nutrition.2022; 74(1): 72.     CrossRef
  • Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis
    Gerd R. Burmester, Kenneth B. Gordon, James T. Rosenbaum, Dilek Arikan, Winnie L. Lau, Peigang Li, Freddy Faccin, Remo Panaccione
    Advances in Therapy.2020; 37(1): 364.     CrossRef
  • Comparative Evaluation of 4 Commercially Available ELISA Kits for Measuring Adalimumab and Anti-adalimumab Antibodies
    Melissa Joyce Sam, Susan Jane Connor, Watson Wa-Sang Ng, Catherine Mei-Ling Toong
    Therapeutic Drug Monitoring.2020; 42(6): 821.     CrossRef
  • Nonimmunity against hepatitis B virus infection in patients newly diagnosed with inflammatory bowel disease
    Seong Jae Yeo, Hyun Seok Lee, Byung Ik Jang, Eun Soo Kim, Seong Woo Jeon, Sung Kook Kim, Kyeong Ok Kim, Yoo Jin Lee, Hyun Jik Lee, Kyung Sik Park, Yun Jin Jung, Eun Young Kim, Chang Heon Yang
    Intestinal Research.2018; 16(3): 400.     CrossRef
  • Updated treatment strategies for intestinal Behçet’s disease
    Yong Eun Park, Jae Hee Cheon
    The Korean Journal of Internal Medicine.2018; 33(1): 1.     CrossRef
  • Changing treatment paradigms for the management of inflammatory bowel disease
    Jong Pil Im, Byong Duk Ye, You Sun Kim, Joo Sung Kim
    The Korean Journal of Internal Medicine.2018; 33(1): 28.     CrossRef
  • Long-Term Outcomes of Adalimumab Treatment in 254 Patients with Crohn’s Disease: A Hospital-Based Cohort Study from Korea
    Hyungil Seo, Byong Duk Ye, Eun Mi Song, Sun-Ho Lee, Kiju Chang, Ho-Su Lee, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Kyung-Jo Kim, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang
    Digestive Diseases and Sciences.2017; 62(10): 2882.     CrossRef
  • Rare occurrence of inflammatory bowel disease in a cohort of Han Chinese ankylosing spondylitis patients- a single institute study
    Chrong-Reen Wang, Chia-Tse Weng, Chung-Ta Lee, Kuo-Yuan Huang, Sheng-Min Hsu, Ming-Fei Liu
    Scientific Reports.2017;[Epub]     CrossRef
  • 6,721 View
  • 96 Download
  • 11 Web of Science
  • 11 Crossref
Close layer

Intest Res : Intestinal Research
Close layer
TOP